- Issue:June 2010
Massachusetts the Site of Latest Clash over Premiums
Although 4 of the state’s largest health insurers posted first-quarter losses that they attributed mostly to Governor Deval Patrick’s efforts to slow premium growth rates for individuals and small businesses, the Massachusetts Division of Insurance is holding firm on its decision to deny insurers’ requests for premium increases. Insurers challenging the rejections assert that premium increases are a direct and necessary result of the rising cost of medical care and say the denials amount to arbitrary price contro
- Issue:June 2010
Increases in Enrollment and Assets Continue
Led by growth among large-group insurers, enrollment in high-deductible health plans (HDHPs) and associated health savings accounts (HSAs) exceeded 10 million this year. Separate research projects recently conducted by America’s Health Insurance Plans (AHIP) and the Employee Benefit Research Institute (EBRI) quantify expansion in both the number and value of HSAs. After several years of increases, the continued expansion of HDHP/HSA arrangements may depend on how new regulations issuing from national healthcare reforms influe
Managed Care Calendar
- AAPM 2010 Clinical Meeting
Poll
Current Issue
Healthcare News
GENOMIC-BASED ASSAYS ON DEMAND WEBCASTS
UNDERSTANDING OPIOID DEPENDENCE: Outcomes from HereToHelp
The Drug Addiction Treatment Act of
2000 (DATA 2000) was a groundbreaking
piece of legislation that allowed
physicians to prescribe schedule III-V
narcotics for the office-based opioid treatment
(OBOT) of opioid dependence. Treatment
without narcotics was already allowable.
However, narcotics were made illegal
under the Harrison Narcotic Act. As a result
of the FDA approving a schedule III-IV for
the treatment of opioid dependence, Suboxone
® (buprenorphine/naloxone) CIII and Subutex
® (buprenorphine) CIII became the only
agents available to physicians who have been
granted the
Medicare-Medicaid
REQUIP XL is an oral dopamine agonist medication for Parkinson’s disease and had demonstrated significant improvement in the symptoms of Parkinson’s disease.
The Role of Immune Function in the Changing Landscape of RRMS Therapies
Gastroesophageal reflux disease (GERD) is an important
managed care health concern because it is one of the most common gastrointestinal (GI) disorders in the United
States. GERD affects nearly 18.6 million Americans, according to a national healthcare database analysis.
Parkinson’s disease (PD) is a progressive
and disabling neurologic disorder. The disease is the most prevalent type of parkinsonism, a clinical syndrome caused by lesions in the basal ganglia, predominantly in the substantia nigra, which produces deficits in motor behavior.
